PMID- 31326491
OWN - NLM
STAT- MEDLINE
DCOM- 20201109
LR  - 20230918
IS  - 1876-7591 (Electronic)
IS  - 1876-7591 (Linking)
VI  - 13
IP  - 2 Pt 1
DP  - 2020 Feb
TI  - The Prognostic Role of Late Gadolinium Enhancement in Aortic Stenosis: A 
      Systematic Review and Meta-Analysis.
PG  - 385-392
LID - S1936-878X(19)30438-3 [pii]
LID - 10.1016/j.jcmg.2019.03.029 [doi]
AB  - OBJECTIVES: The aim of this systematic review was to explore the prognostic value 
      of late gadolinium enhancement (LGE) in patients with aortic stenosis (AS). 
      BACKGROUND: Myocardial fibrosis is a common feature of many cardiac diseases. 
      Cardiac magnetic resonance (CMR) has the ability to noninvasively detect regional 
      fibrosis by using the LGE technique. Several studies have explored whether LGE is 
      associated with adverse outcome in patients with AS. METHODS: Electronic 
      databases were searched to identify studies investigating the ability of LGE to 
      predict all-cause mortality in patients with AS. A random effects model 
      meta-analysis was conducted. Heterogeneity was assessed with the I(2) statistic. 
      RESULTS: Six studies comprising 1,151 patients met our inclusion criteria. LGE 
      was present in 49.1% of patients with AS. In the pooled analysis, LGE was found 
      to be a strong univariate predictor of all-cause mortality (pooled unadjusted 
      odds ratio: 2.56; 95% confidence interval: 1.83 to 3.57; I(2) = 0%). Four of the 
      included studies reported adjusted hazard ratios for mortality. LGE was 
      independently associated with mortality, even after adjusting for baseline 
      characteristics (pooled adjusted hazard ratio: 2.50; 95% confidence interval: 
      1.64 to 3.83; I(2) = 0%). CONCLUSIONS: Fibrosis on LGE-CMR is a powerful 
      predictor of all-cause mortality in patients with AS and may serve as a novel 
      marker for risk stratification. Future studies should explore whether LGE-CMR can 
      also be used to optimize timing of AS-related interventions.
CI  - Copyright (c) 2020. Published by Elsevier Inc.
FAU - Papanastasiou, Christos A
AU  - Papanastasiou CA
AD  - 1st Department of Cardiology, AHEPA Hospital, Aristotle University of 
      Thessaloniki, Thessaloniki, Greece.
FAU - Kokkinidis, Damianos G
AU  - Kokkinidis DG
AD  - Department of Medicine, Jacobi Medical Center, Albert Einstein College of 
      Medicine, Bronx, New York.
FAU - Kampaktsis, Polydoros N
AU  - Kampaktsis PN
AD  - New York Presbyterian Hospital/Weill Cornell Medical College, Department of 
      Medicine, New York, New York.
FAU - Bikakis, Iosif
AU  - Bikakis I
AD  - 401 General Military Hospital of Athens, Athens, Greece; Society of Junior 
      Doctors, Athens, Greece.
FAU - Cunha, Daniela K
AU  - Cunha DK
AD  - Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, 
      Leeds, United Kingdom; Department of Radiology, University of Iowa Hospital and 
      Clinics, Iowa City, Iowa.
FAU - Oikonomou, Evangelos K
AU  - Oikonomou EK
AD  - Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, 
      Leeds, United Kingdom.
FAU - Greenwood, John P
AU  - Greenwood JP
AD  - Department of Radiology, University of Iowa Hospital and Clinics, Iowa City, 
      Iowa.
FAU - Garcia, Mario J
AU  - Garcia MJ
AD  - Division of Cardiology, Department of Medicine, Jacobi Medical Center, Albert 
      Einstein College of Medicine, Bronx, New York.
FAU - Karamitsos, Theodoros D
AU  - Karamitsos TD
AD  - 1st Department of Cardiology, AHEPA Hospital, Aristotle University of 
      Thessaloniki, Thessaloniki, Greece. Electronic address: tkaramitsos@auth.gr.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
PT  - Systematic Review
DEP - 20190717
PL  - United States
TA  - JACC Cardiovasc Imaging
JT  - JACC. Cardiovascular imaging
JID - 101467978
RN  - 0 (Contrast Media)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
CIN - JACC Cardiovasc Imaging. 2020 Feb;13(2 Pt 1):393-394. PMID: 31326494
MH  - Aged
MH  - Aortic Valve Stenosis/*diagnostic imaging/mortality/pathology/physiopathology
MH  - Contrast Media/*administration & dosage
MH  - Female
MH  - Fibrosis
MH  - Gadolinium/*administration & dosage
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Myocardium/*pathology
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Assessment
MH  - Risk Factors
MH  - Severity of Illness Index
MH  - Ventricular Function, Left
MH  - Ventricular Remodeling
OTO - NOTNLM
OT  - aortic stenosis
OT  - cardiac magnetic resonance
OT  - late gadolinium enhancement
OT  - meta-analysis
EDAT- 2019/07/22 06:00
MHDA- 2020/11/11 06:00
CRDT- 2019/07/22 06:00
PHST- 2018/09/10 00:00 [received]
PHST- 2019/03/20 00:00 [revised]
PHST- 2019/03/21 00:00 [accepted]
PHST- 2019/07/22 06:00 [pubmed]
PHST- 2020/11/11 06:00 [medline]
PHST- 2019/07/22 06:00 [entrez]
AID - S1936-878X(19)30438-3 [pii]
AID - 10.1016/j.jcmg.2019.03.029 [doi]
PST - ppublish
SO  - JACC Cardiovasc Imaging. 2020 Feb;13(2 Pt 1):385-392. doi: 
      10.1016/j.jcmg.2019.03.029. Epub 2019 Jul 17.